SCHEMBL26812845

SCHEMBL26812845

O=c1ccc(S(=O)(=O)Nc2nc(Oc3ccccc3)cc(-c3ccccc3)n2)c[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.51
▸ MAPK1 P28482 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ ATM Q13315 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ GPR39 O43194 1/20 0.39
▸ PGR P06401 1/20 0.39
▸ XDH P47989 1/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ KDM4E B2RXH2 3/20 0.37
▸ LMNA P02545 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26806813 0.85 MAPT (0.61) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL24309572 0.82 MAPT (0.50) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL26813023 0.82 MAPT (0.58) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL24310173 0.82 MAPT (0.77) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL26813034 0.81 MAPT (0.57) MAPTMAPK1TDP1ALDH1A1SMN1; SMN2
SCHEMBL26813005 0.81 MAPT (0.56) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL26813029 0.79 MAPT (0.55) MAPTMAPK1TDP1CYP1A2CYP2C9
SCHEMBL26812660 0.79 MAPT (0.58) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL26813018 0.79 MAPT (0.55) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL26880277 0.79 MAPK1 (0.47) MAPTMAPK1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B MAPT 4864/4885MAPK1 3810/4885TDP1 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback